2.4. Endpoints
The primary efficacy endpoint was a percentage change in LDL cholesterol level from baseline to an 8-week follow-up. Secondary efficacy endpoints included changes in the following variables: LDL cholesterol at a 4-week follow-up, and total cholesterol, high-density lipoprotein (HDL) cholesterol, triglyceride, non-HDL cholesterol, apolipoprotein A1, apolipoprotein B, and LDL cholesterol goal achievement at 4- and 8-week follow-up. The treatment goal of LDL cholesterol was individualized according to the risk category (Supplementary Table 2, 